You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

140 Results
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: GL 3-20
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: 2.1
Sep 2021
Guidelines and Advice
Status: Current
Version: 2
Dec 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Gemtuzumab Ozogamicin (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DAUNOrubicin,
cytarabine,
gemtuzumab ozogamicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2021
Guidelines and Advice
Status: Current
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Curative, Adjuvant
Drugs Used:
riTUXimab (Unfunded),
gemcitabine,
oxaliplatin,
riTUXimab (subcut) (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2021
Cancer facts
Jan 2021
Cancer facts
Jan 2021
Guidelines and Advice
Status: Current
ID: 7-A-2018-3
Feb 2021

Pages